ArticlePloS one2013
Few single nucleotide variations in exomes of human cord blood induced pluripotent stem cells.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of the last two decades of NK cell-based clinical trials: state of the art of AML therapy.BMC cancer · 2025Pooled it
- G2B: an optimized lentiviral vector with enhanced titer and β-globin expression for improved β-thalassemia gene therapy.Blood science (Baltimore, Md.) · 2025Article
- Genes as Genome Stabilizers in Pluripotent Stem Cells.Advances in experimental medicine and biology · 2025Review
- Generation of a bank of clinical-grade, HLA-homozygous iPSC lines with high coverage of the Spanish population.Stem cell research & therapy · 2023Article
- Enhancing cord blood stem cell-derived NK cell growth and differentiation through hyperosmosis.Stem cell research & therapy · 2023Article
- Human Induced Pluripotent Stem Cells: From Cell Origin, Genomic Stability, and Epigenetic Memory to Translational Medicine.Stem cells (Dayton, Ohio) · 2022Review
- Tissue-Restricted Stem Cells as Starting Cell Source for Efficient Generation of Pluripotent Stem Cells: An Overview.Advances in experimental medicine and biology · 2022Review
- The Impact of Acquired Genetic Abnormalities on the Clinical Translation of Human Pluripotent Stem Cells.Cells · 2021Review
- Reprogramming enriches for somatic cell clones with small-scale mutations in cancer-associated genes.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Genomic integrity of human induced pluripotent stem cells: Reprogramming, differentiation and applications.World journal of stem cells · 2019Review
- How Does Reprogramming to Pluripotency Affect Genomic Imprinting?Frontiers in cell and developmental biology · 2019Review
- Highly efficient genome editing via CRISPR-Cas9 in human pluripotent stem cells is achieved by transient BCL-XL overexpression.Nucleic acids research · 2018Article
- Next-generation sequencing traces human induced pluripotent stem cell lines clonally generated from heterogeneous cancer tissue.World journal of stem cells · 2017Article
- Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications.Stem cell reviews and reports · 2017Review
- Enhanced Generation of Integration-free iPSCs from Human Adult Peripheral Blood Mononuclear Cells with an Optimal Combination of Episomal Vectors.Stem cell reports · 2016Article
- Article
- Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies.Stem cells translational medicine · 2015Review
- The Royan Public Umbilical Cord Blood Bank: Does It Cover All Ethnic Groups in Iran Based on HLA Diversity?Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2014Article
- Cellular reprogramming of human peripheral blood cells.Genomics, proteomics & bioinformatics · 2013Review
- Efficient generation of integration-free ips cells from human adult peripheral blood using BCL-XL together with Yamanaka factors.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effect of the cellular reprogramming process per se on mutation load remains unclear. To address this issue, we performed whole exome sequencing analysis of induced pluripotent stem cells (iPSCs) reprogrammed from human cord blood (CB) CD34(+) cells. Cells from a single donor and improved lentiviral vectors for high-efficiency (2-14%) reprogramming were used to examine the effects of three different combinations of reprogramming factors: OCT4 and SOX2 (OS), OS and ZSCAN4 (OSZ), OS and MYC and KLF4 (OSMK). Five clones from each group were subject to whole exome sequencing analysis. We identified 14, 11, and 9 single nucleotide variations (SNVs), in exomes, including untranslated regions (UTR), in the five clones of OSMK, OS, and OSZ iPSC lines. Only 8, 7, and 4 of these, respectively, were protein-coding mutations. An average of 1.3 coding mutations per CB iPSC line is remarkably lower than previous studies using fibroblasts and low-efficiency reprogramming approaches. These data demonstrate that point nucleotide mutations during cord blood reprogramming are negligible and that the inclusion of genome stabilizers like ZSCAN4 during reprogramming may further decrease reprogramming-associated mutations. Our findings provide evidence that CB is a superior source of cells for iPSC banking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.